Vir Biotechnology
210 hedge funds and large institutions have $3.25B invested in Vir Biotechnology in 2021 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 77 increasing their positions, 57 reducing their positions, and 23 closing their positions.
157% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 23
35% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 57
20% more funds holding
Funds holding: 175 → 210 (+35)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
2.65% more ownership
Funds ownership: 57.02% → 59.67% (+2.7%)
0% more capital invested
Capital invested by funds: $3.24B → $3.25B (+$10.1M)
3% less call options, than puts
Call options by funds: $37M | Put options by funds: $38.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$79.7M |
| 2 |
Morgan Stanley
New York
|
+$42.6M |
| 3 |
Millennium Management
New York
|
+$31.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$18.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$126M |
| 2 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
-$49.8M |
| 3 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$15.7M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$12.6M |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$11.7M |
VIR Hedge Fund Activity: Q4 2021 in Review
210 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q4 2021, worth a combined $3.25B — up 0.31% from $3.24B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new VIR positions and 23 closed out — a net gain of 36 holders — while 77 added to existing stakes and 57 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $79.7M. The largest seller was Capital International Investors, cutting an estimated $126M.
- 210 institutional investors held Vir Biotechnology (VIR) as of Q4 2021, up from 175 in Q3 2021.
- Funds reported $3.25B of Vir Biotechnology stock for Q4 2021, up 0.31% quarter-over-quarter.
- 59 funds opened new Vir Biotechnology positions in Q4 2021 and 23 closed out, a net change of +36 holders.
- The largest Vir Biotechnology buyer in Q4 2021 was Point72 Asset Management, an estimated $79.7M added.
- The largest Vir Biotechnology seller in Q4 2021 was Capital International Investors, an estimated $126M sold.
Based on aggregated 13F filings for Q4 2021.